01
VPAC1/2
VIP activates VPAC receptors and affects vascular tone, secretion and immune signalling.
Vasoactive intestinal peptide, 28 amino acids
VIP / Aviptadil
VPAC1/2
VIP is an endogenous neuropeptide affecting vascular tone, smooth muscle, secretion and immune signalling. Aviptadil is the synthetic form studied for specific indications; different routes and conditions do not share an interchangeable dosing protocol.
1Overview
-Reference frequency
DataSmall physiological and clinical studies
Research status
No general dosing protocol or broad approval
VIP AVIPTADIL5 MG
01 · Overview
What is VIP / Aviptadil?
VIP is an endogenous neuropeptide affecting vascular tone, smooth muscle, secretion and immune signalling. Aviptadil is the synthetic form studied for specific indications; different routes and conditions do not share an interchangeable dosing protocol.
Research route, formulation and population determine what a result actually means.
Protocol status: Not found as a standalone product page in the previously used protocol source. No protocol has been invented; only a transparent calculation reference is shown where technically meaningful.
02 · Research
What do the studies show?
Small physiological and clinical studies. Educational information. Not diagnosis, treatment or use advice.
Inhaled
Human researchPulmonary haemodynamics
Small studies examined acute effects of inhaled aviptadil in pulmonary hypertension; this does not establish a general injection protocol.
Phase 3
Limited evidenceRespiratory failure
Randomised COVID-19 trials produced mixed findings and do not support broad use outside the studied context.
03 · DATA
Peptide and product specifications
Checked identity data for this research compound or blend.
VIP / AviptadilPeptide and product specifications
Molecular formula
C₁₄₇H₂₃₈N₄₄O₄₂S
Molecular weight
3325.7 g/mol
CAS number
40077-57-4
Amino-acid sequence / components
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂
Amino-acid count
28
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference form
White lyophilised powder
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data
These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.
04 · Calculator
Reconstitution and U-100 conversion
This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.
Calculator
No protocol established for this vial
1
2
3
4
Draw to
0 units
0.00 mL
VIP AVIPTADIL
5 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION
How to reconstitute VIP / Aviptadil for laboratory research
A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.
Clean
Disinfect the rubber closures of both vials and allow them to dry.
Measure diluent
Withdraw only the diluent validated for the specific compound.
Add slowly
Let the liquid run slowly down the inside wall of the vial.
Swirl gently
Do not shake; rotate gently until the material has dissolved.
Store per protocol
Follow the product label, COA and validated stability data.
Important checks before and after reconstitution
Check the product
First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.
Use clean, sterile technique
Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.
Concentration, not total amount
The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.
Inspect and label
Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.
General reconstitution volumes listed by the source
General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.
| Vial strength | Commonly listed volume |
|---|---|
| 2 mg | 1–2 mL |
| 5 mg | 2–3 mL |
| 6 mg | 2–3 mL |
| 10 mg | 2–4 mL |
| 15 mg | 3–5 mL |
| 20 mg | 4–8 mL |
Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.
Protocol status: Not found as a standalone product page in the previously used protocol source. No protocol has been invented; only a transparent calculation reference is shown where technically meaningful.
05 · Safety and limitations
Safety and limitations
Research route, formulation and population determine what a result actually means.
What is known
- Visible research claims use primary or official sources.
- The calculator is arithmetic and does not turn a study amount into medical advice.
- A registered medicine and a research vial are not automatically equivalent.
What remains uncertain
- Many products lack long-term safety data and independent replication.
- Animal and cell findings do not predict a safe human dose.
- Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: No general dosing protocol or broad approval. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ
Frequently asked questions
VIP is an endogenous neuropeptide affecting vascular tone, smooth muscle, secretion and immune signalling. Aviptadil is the synthetic form studied for specific indications; different routes and conditions do not share an interchangeable dosing protocol.
Small studies examined acute effects of inhaled aviptadil in pulmonary hypertension; this does not establish a general injection protocol. Randomised COVID-19 trials produced mixed findings and do not support broad use outside the studied context.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources
Primary research sources
Educational information. Not diagnosis, treatment or use advice.